LYEL

Lyell Immunopharma, Inc.

NasdaqGSUSDEQUITY DELAYED

15.53

▲ 0.18 (1.17%)

MARKET · —

Price

Open

15.35

Prev close

15.35

Day high

16.16

Day low

15.20

Volume

99.05K

Market cap

—

P/E (TTM)

—

52W range

10.56 – 45.00

Trailing performance

Price return · vs SPY

Returnvs SPY

+11.33% +12.7%

+21.52% +17.8%

-10.23% -13.3%

-27.43% -38.5%

YTD

-49.55% -61.8%

+45.82% +25.8%

-65.49% -139.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

14.71

+5.61% from price

SMA 20

14.07

+10.35% from price

SMA 50

13.69

+13.44% from price

SMA 100

16.60

-6.43% from price

SMA 200

20.43

-23.97% from price

EMA 12

14.70

+5.64% from price

EMA 26

14.27

+8.79% from price

EMA 50

14.56

+6.65% from price

RSI (14)

59.4

Neutral

MACD (12,26,9)

0.43

Hist 0.22

ATR (14)

1.17

7.51% of price

Realised vol 30D

71.1%

Annualised

Bollinger upper

15.98

20, 2σ

Bollinger lower

12.17

20, 2σ

50 / 200 cross

Death

13.69 vs 20.43

Trend bias

Below 200

-23.97%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.70

More volatile than market

Correlation to SPY

0.27

Largely independent

Realised vol 30D

71.1%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-69.9%

Peak to trough

Max drawdown 5Y

-97.8%

Peak to trough

ATR 14

1.17

7.51% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 15.53

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

LYEL · links out to the publisher

Lyell Immunopharma: Q2 Earnings Snapshot Associated Press · 16d ago Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 GlobeNewswire · 16d ago Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls The Fly · 16d ago Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More 24/7 Wall St. · 16d ago Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target MT Newswires · 16d ago B. Riley Initiates Lyell Immunopharma at Buy With $44 Price Target MT Newswires · 31d ago Lyell Immunopharma Files for Secondary Offering of Common Shares MT Newswires · 40d ago AbCellera Appoints Dr. Lynn Seely to its Board of Directors Business Wire · 47d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.